A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 2

Conditions

Neuralgia, Postherpetic

Treatments

Drug: MK0686

Study type

Interventional

Funder types

Industry

Identifiers

NCT00282763

0686-005

2005_090

Details and patient eligibility

About

The purpose of this Study is to test the Safety and Effectiveness of MK0686 in relieving neuropathic (chronic) pain as experienced by patients with Postherpetic Neuralgia (Also Know as PHN or Post Shingles Pain).

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Enrollment

12 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of postherpetic neuralgia with pain having lasted at least 6 months
Able to complete study questionnaires, patient diary, and comply with daily study medication
Patient is not satisfied with current treatment for pain control

Exclusion criteria

Pregnant or nursing female
History of evidence of a condition that in the opinion of the investigator, may interfere with the study results (e.g., diabetic neuropathy of fibromyalgia) or pose undue risk to undergo the course of medication required by the study (e.g., unstable heart disease, morbid obesity, kidney or liver disease)